 | • レポートコード：QYR2104Z0099 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥553,800 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥830,700 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,107,600 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、ADHD治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（覚醒剤、非覚醒剤）、用途別市場規模（成人、子供）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・ADHD治療薬の市場動向 ・企業の競争状況、市場シェア ・ADHD治療薬の種類別市場規模（覚醒剤、非覚醒剤） ・ADHD治療薬の用途別市場規模（成人、子供） ・ADHD治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・ADHD治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・ADHD治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ADHD治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・ADHD治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amneal Pharmaceuticals、Eli Lilly and Co.、Johnson and Johnson Services、NEOS Therapeutic、Takeda Pharmaceutical、Pfizer、Lupin、Shire、Mallinckrodt） ・結論 |
ADHD medications can help reduce symptoms of hyperactivity, inattentiveness, and impulsivity in children and adults with attention deficit hyperactivity disorder (ADHD), formerly known as ADD.
Market Analysis and Insights: Global ADHD Medications Market
The global ADHD Medications market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global ADHD Medications market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global ADHD Medications market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global ADHD Medications market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global ADHD Medications market.
Global ADHD Medications Scope and Market Size
ADHD Medications market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global ADHD Medications market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Stimulant
Non-stimulant
Segment by Application
Adult
Children
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Amneal Pharmaceuticals
Eli Lilly and Co.
Johnson and Johnson Services
NEOS Therapeutic
Takeda Pharmaceutical
Pfizer
Lupin
Shire
Mallinckrodt
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ADHD Medications Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Stimulant
1.2.3 Non-stimulant
1.3 Market by Application
1.3.1 Global ADHD Medications Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Adult
1.3.3 Children
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global ADHD Medications Market Perspective (2016-2027)
2.2 ADHD Medications Growth Trends by Regions
2.2.1 ADHD Medications Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 ADHD Medications Historic Market Share by Regions (2016-2021)
2.2.3 ADHD Medications Forecasted Market Size by Regions (2022-2027)
2.3 ADHD Medications Industry Dynamic
2.3.1 ADHD Medications Market Trends
2.3.2 ADHD Medications Market Drivers
2.3.3 ADHD Medications Market Challenges
2.3.4 ADHD Medications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ADHD Medications Players by Revenue
3.1.1 Global Top ADHD Medications Players by Revenue (2016-2021)
3.1.2 Global ADHD Medications Revenue Market Share by Players (2016-2021)
3.2 Global ADHD Medications Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by ADHD Medications Revenue
3.4 Global ADHD Medications Market Concentration Ratio
3.4.1 Global ADHD Medications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ADHD Medications Revenue in 2020
3.5 ADHD Medications Key Players Head office and Area Served
3.6 Key Players ADHD Medications Product Solution and Service
3.7 Date of Enter into ADHD Medications Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ADHD Medications Breakdown Data by Type
4.1 Global ADHD Medications Historic Market Size by Type (2016-2021)
4.2 Global ADHD Medications Forecasted Market Size by Type (2022-2027)
5 ADHD Medications Breakdown Data by Application
5.1 Global ADHD Medications Historic Market Size by Application (2016-2021)
5.2 Global ADHD Medications Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America ADHD Medications Market Size (2016-2027)
6.2 North America ADHD Medications Market Size by Type
6.2.1 North America ADHD Medications Market Size by Type (2016-2021)
6.2.2 North America ADHD Medications Market Size by Type (2022-2027)
6.2.3 North America ADHD Medications Market Size by Type (2016-2027)
6.3 North America ADHD Medications Market Size by Application
6.3.1 North America ADHD Medications Market Size by Application (2016-2021)
6.3.2 North America ADHD Medications Market Size by Application (2022-2027)
6.3.3 North America ADHD Medications Market Size by Application (2016-2027)
6.4 North America ADHD Medications Market Size by Country
6.4.1 North America ADHD Medications Market Size by Country (2016-2021)
6.4.2 North America ADHD Medications Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe ADHD Medications Market Size (2016-2027)
7.2 Europe ADHD Medications Market Size by Type
7.2.1 Europe ADHD Medications Market Size by Type (2016-2021)
7.2.2 Europe ADHD Medications Market Size by Type (2022-2027)
7.2.3 Europe ADHD Medications Market Size by Type (2016-2027)
7.3 Europe ADHD Medications Market Size by Application
7.3.1 Europe ADHD Medications Market Size by Application (2016-2021)
7.3.2 Europe ADHD Medications Market Size by Application (2022-2027)
7.3.3 Europe ADHD Medications Market Size by Application (2016-2027)
7.4 Europe ADHD Medications Market Size by Country
7.4.1 Europe ADHD Medications Market Size by Country (2016-2021)
7.4.2 Europe ADHD Medications Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific ADHD Medications Market Size (2016-2027)
8.2 Asia-Pacific ADHD Medications Market Size by Type
8.2.1 Asia-Pacific ADHD Medications Market Size by Type (2016-2021)
8.2.2 Asia-Pacific ADHD Medications Market Size by Type (2022-2027)
8.2.3 Asia-Pacific ADHD Medications Market Size by Type (2016-2027)
8.3 Asia-Pacific ADHD Medications Market Size by Application
8.3.1 Asia-Pacific ADHD Medications Market Size by Application (2016-2021)
8.3.2 Asia-Pacific ADHD Medications Market Size by Application (2022-2027)
8.3.3 Asia-Pacific ADHD Medications Market Size by Application (2016-2027)
8.4 Asia-Pacific ADHD Medications Market Size by Region
8.4.1 Asia-Pacific ADHD Medications Market Size by Region (2016-2021)
8.4.2 Asia-Pacific ADHD Medications Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America ADHD Medications Market Size (2016-2027)
9.2 Latin America ADHD Medications Market Size by Type
9.2.1 Latin America ADHD Medications Market Size by Type (2016-2021)
9.2.2 Latin America ADHD Medications Market Size by Type (2022-2027)
9.2.3 Latin America ADHD Medications Market Size by Type (2016-2027)
9.3 Latin America ADHD Medications Market Size by Application
9.3.1 Latin America ADHD Medications Market Size by Application (2016-2021)
9.3.2 Latin America ADHD Medications Market Size by Application (2022-2027)
9.3.3 Latin America ADHD Medications Market Size by Application (2016-2027)
9.4 Latin America ADHD Medications Market Size by Country
9.4.1 Latin America ADHD Medications Market Size by Country (2016-2021)
9.4.2 Latin America ADHD Medications Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ADHD Medications Market Size (2016-2027)
10.2 Middle East & Africa ADHD Medications Market Size by Type
10.2.1 Middle East & Africa ADHD Medications Market Size by Type (2016-2021)
10.2.2 Middle East & Africa ADHD Medications Market Size by Type (2022-2027)
10.2.3 Middle East & Africa ADHD Medications Market Size by Type (2016-2027)
10.3 Middle East & Africa ADHD Medications Market Size by Application
10.3.1 Middle East & Africa ADHD Medications Market Size by Application (2016-2021)
10.3.2 Middle East & Africa ADHD Medications Market Size by Application (2022-2027)
10.3.3 Middle East & Africa ADHD Medications Market Size by Application (2016-2027)
10.4 Middle East & Africa ADHD Medications Market Size by Country
10.4.1 Middle East & Africa ADHD Medications Market Size by Country (2016-2021)
10.4.2 Middle East & Africa ADHD Medications Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amneal Pharmaceuticals
11.1.1 Amneal Pharmaceuticals Company Details
11.1.2 Amneal Pharmaceuticals Business Overview
11.1.3 Amneal Pharmaceuticals ADHD Medications Introduction
11.1.4 Amneal Pharmaceuticals Revenue in ADHD Medications Business (2016-2021)
11.1.5 Amneal Pharmaceuticals Recent Development
11.2 Eli Lilly and Co.
11.2.1 Eli Lilly and Co. Company Details
11.2.2 Eli Lilly and Co. Business Overview
11.2.3 Eli Lilly and Co. ADHD Medications Introduction
11.2.4 Eli Lilly and Co. Revenue in ADHD Medications Business (2016-2021)
11.2.5 Eli Lilly and Co. Recent Development
11.3 Johnson and Johnson Services
11.3.1 Johnson and Johnson Services Company Details
11.3.2 Johnson and Johnson Services Business Overview
11.3.3 Johnson and Johnson Services ADHD Medications Introduction
11.3.4 Johnson and Johnson Services Revenue in ADHD Medications Business (2016-2021)
11.3.5 Johnson and Johnson Services Recent Development
11.4 NEOS Therapeutic
11.4.1 NEOS Therapeutic Company Details
11.4.2 NEOS Therapeutic Business Overview
11.4.3 NEOS Therapeutic ADHD Medications Introduction
11.4.4 NEOS Therapeutic Revenue in ADHD Medications Business (2016-2021)
11.4.5 NEOS Therapeutic Recent Development
11.5 Takeda Pharmaceutical
11.5.1 Takeda Pharmaceutical Company Details
11.5.2 Takeda Pharmaceutical Business Overview
11.5.3 Takeda Pharmaceutical ADHD Medications Introduction
11.5.4 Takeda Pharmaceutical Revenue in ADHD Medications Business (2016-2021)
11.5.5 Takeda Pharmaceutical Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer ADHD Medications Introduction
11.6.4 Pfizer Revenue in ADHD Medications Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Lupin
11.7.1 Lupin Company Details
11.7.2 Lupin Business Overview
11.7.3 Lupin ADHD Medications Introduction
11.7.4 Lupin Revenue in ADHD Medications Business (2016-2021)
11.7.5 Lupin Recent Development
11.8 Shire
11.8.1 Shire Company Details
11.8.2 Shire Business Overview
11.8.3 Shire ADHD Medications Introduction
11.8.4 Shire Revenue in ADHD Medications Business (2016-2021)
11.8.5 Shire Recent Development
11.9 Mallinckrodt
11.9.1 Mallinckrodt Company Details
11.9.2 Mallinckrodt Business Overview
11.9.3 Mallinckrodt ADHD Medications Introduction
11.9.4 Mallinckrodt Revenue in ADHD Medications Business (2016-2021)
11.9.5 Mallinckrodt Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global ADHD Medications Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Stimulant
Table 3. Key Players of Non-stimulant
Table 4. Global ADHD Medications Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global ADHD Medications Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global ADHD Medications Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global ADHD Medications Market Share by Regions (2016-2021)
Table 8. Global ADHD Medications Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global ADHD Medications Market Share by Regions (2022-2027)
Table 10. ADHD Medications Market Trends
Table 11. ADHD Medications Market Drivers
Table 12. ADHD Medications Market Challenges
Table 13. ADHD Medications Market Restraints
Table 14. Global ADHD Medications Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global ADHD Medications Market Share by Players (2016-2021)
Table 16. Global Top ADHD Medications Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ADHD Medications as of 2020)
Table 17. Ranking of Global Top ADHD Medications Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by ADHD Medications Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players ADHD Medications Product Solution and Service
Table 21. Date of Enter into ADHD Medications Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global ADHD Medications Market Size by Type (2016-2021) (US$ Million)
Table 24. Global ADHD Medications Revenue Market Share by Type (2016-2021)
Table 25. Global ADHD Medications Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global ADHD Medications Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global ADHD Medications Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global ADHD Medications Revenue Market Share by Application (2016-2021)
Table 29. Global ADHD Medications Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global ADHD Medications Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America ADHD Medications Market Size by Type (2016-2021) (US$ Million)
Table 32. North America ADHD Medications Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America ADHD Medications Market Size by Application (2016-2021) (US$ Million)
Table 34. North America ADHD Medications Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America ADHD Medications Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America ADHD Medications Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe ADHD Medications Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe ADHD Medications Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe ADHD Medications Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe ADHD Medications Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe ADHD Medications Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe ADHD Medications Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific ADHD Medications Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific ADHD Medications Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific ADHD Medications Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific ADHD Medications Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific ADHD Medications Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific ADHD Medications Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America ADHD Medications Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America ADHD Medications Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America ADHD Medications Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America ADHD Medications Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America ADHD Medications Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America ADHD Medications Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa ADHD Medications Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa ADHD Medications Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa ADHD Medications Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa ADHD Medications Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa ADHD Medications Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa ADHD Medications Market Size by Country (2022-2027) & (US$ Million)
Table 61. Amneal Pharmaceuticals Company Details
Table 62. Amneal Pharmaceuticals Business Overview
Table 63. Amneal Pharmaceuticals ADHD Medications Product
Table 64. Amneal Pharmaceuticals Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 65. Amneal Pharmaceuticals Recent Development
Table 66. Eli Lilly and Co. Company Details
Table 67. Eli Lilly and Co. Business Overview
Table 68. Eli Lilly and Co. ADHD Medications Product
Table 69. Eli Lilly and Co. Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 70. Eli Lilly and Co. Recent Development
Table 71. Johnson and Johnson Services Company Details
Table 72. Johnson and Johnson Services Business Overview
Table 73. Johnson and Johnson Services ADHD Medications Product
Table 74. Johnson and Johnson Services Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 75. Johnson and Johnson Services Recent Development
Table 76. NEOS Therapeutic Company Details
Table 77. NEOS Therapeutic Business Overview
Table 78. NEOS Therapeutic ADHD Medications Product
Table 79. NEOS Therapeutic Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 80. NEOS Therapeutic Recent Development
Table 81. Takeda Pharmaceutical Company Details
Table 82. Takeda Pharmaceutical Business Overview
Table 83. Takeda Pharmaceutical ADHD Medications Product
Table 84. Takeda Pharmaceutical Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 85. Takeda Pharmaceutical Recent Development
Table 86. Pfizer Company Details
Table 87. Pfizer Business Overview
Table 88. Pfizer ADHD Medications Product
Table 89. Pfizer Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 90. Pfizer Recent Development
Table 91. Lupin Company Details
Table 92. Lupin Business Overview
Table 93. Lupin ADHD Medications Product
Table 94. Lupin Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 95. Lupin Recent Development
Table 96. Shire Company Details
Table 97. Shire Business Overview
Table 98. Shire Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 99. Shire Recent Development
Table 100. Mallinckrodt Company Details
Table 101. Mallinckrodt Business Overview
Table 102. Mallinckrodt ADHD Medications Product
Table 103. Mallinckrodt Revenue in ADHD Medications Business (2016-2021) & (US$ Million)
Table 104. Mallinckrodt Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global ADHD Medications Market Share by Type: 2020 VS 2027
Figure 2. Stimulant Features
Figure 3. Non-stimulant Features
Figure 4. Global ADHD Medications Market Share by Application: 2020 VS 2027
Figure 5. Adult Case Studies
Figure 6. Children Case Studies
Figure 7. ADHD Medications Report Years Considered
Figure 8. Global ADHD Medications Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global ADHD Medications Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global ADHD Medications Market Share by Regions: 2020 VS 2027
Figure 11. Global ADHD Medications Market Share by Regions (2022-2027)
Figure 12. Global ADHD Medications Market Share by Players in 2020
Figure 13. Global Top ADHD Medications Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ADHD Medications as of 2020
Figure 14. The Top 10 and 5 Players Market Share by ADHD Medications Revenue in 2020
Figure 15. Global ADHD Medications Revenue Market Share by Type (2016-2021)
Figure 16. Global ADHD Medications Revenue Market Share by Type (2022-2027)
Figure 17. North America ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America ADHD Medications Market Share by Type (2016-2027)
Figure 19. North America ADHD Medications Market Share by Application (2016-2027)
Figure 20. North America ADHD Medications Market Share by Country (2016-2027)
Figure 21. United States ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe ADHD Medications Market Share by Type (2016-2027)
Figure 25. Europe ADHD Medications Market Share by Application (2016-2027)
Figure 26. Europe ADHD Medications Market Share by Country (2016-2027)
Figure 27. Germany ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific ADHD Medications Market Share by Type (2016-2027)
Figure 35. Asia-Pacific ADHD Medications Market Share by Application (2016-2027)
Figure 36. Asia-Pacific ADHD Medications Market Share by Region (2016-2027)
Figure 37. China ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America ADHD Medications Market Share by Type (2016-2027)
Figure 45. Latin America ADHD Medications Market Share by Application (2016-2027)
Figure 46. Latin America ADHD Medications Market Share by Country (2016-2027)
Figure 47. Mexico ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa ADHD Medications Market Share by Type (2016-2027)
Figure 51. Middle East & Africa ADHD Medications Market Share by Application (2016-2027)
Figure 52. Middle East & Africa ADHD Medications Market Share by Country (2016-2027)
Figure 53. Turkey ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE ADHD Medications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Amneal Pharmaceuticals Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 57. Eli Lilly and Co. Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 58. Johnson and Johnson Services Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 59. NEOS Therapeutic Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 60. Takeda Pharmaceutical Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 62. Lupin Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 63. Shire Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 64. Mallinckrodt Revenue Growth Rate in ADHD Medications Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
世界の注意欠陥多動性障害（ADHD）市場規模・現状・予測（2021年-2027年） Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age. There are two main types of drugs used to treat ADH…- 世界の注意欠陥多動性障害（ADHD）市場規模・現状・予測（2021年-2027年） Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age. There are two main types of drugs used to treat ADH…
- 世界のADHD治療市場規模・現状・予測（2021年-2027年） Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnos…
- 世界のADHD治療市場規模・現状・予測（2021年-2027年） Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnos…
- 世界の注意欠陥多動性障害（ADHD）治療市場規模・現状・予測（2021年-2027年） ADHD is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning. G…